Status:
UNKNOWN
DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria
Lead Sponsor:
Hyperfusion
Collaborating Sponsors:
University Hospital, Ghent
Conditions:
Cancer, Lung
Perfusion Computed Tomography Target Lesion
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
DCE-CT of thoracic tumors as an early biomarker for treatment monitoring in comparison with morphologic criteria. 1. Rationale of the clinical investigation For the evaluation of response to anti...
Detailed Description
Introduction Background information Below, you will find an overview the publications on DCE-CT, in the context of the evaluation of treatment effect in cancer patients: Strauch L et al (Diagnostics...
Eligibility Criteria
Inclusion
- Patients suffering from primary malignant thoracic tumoral pathology or second line patients having had a therapy pause of at least 6 weeks; at least one tumoral lesion/component should have ≥15mm in diameter.
- All patients willing to participate and to sign the informed consent.
Exclusion
- All patients younger than 18-years-old.
- Documented allergy for iodine.
- Neutropenia (absolute White Blood Cell count ≤ 1.5 × 109/l).
- Thrombopenia (absolute platelet count ≤ 100 × 109/l).
- Renal insufficiency: serum creatinine ≥ 1.5× the upper limit of normal (ULN); 24-hours creatinine clearance ≤ 50ml/min).
- Serum bilirubine ≥ 1,5 x ULN, AST ≥ 2,5 x ULN, ALT ≥ 2,5x ULN.
- Brain metastases
Key Trial Info
Start Date :
January 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04708483
Start Date
January 7 2021
End Date
December 31 2022
Last Update
February 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital, Ghent
Ghent, East-Flanders, Belgium, 9000